New York Patent of the Month – December 2023
In the realm of neuroscience and therapeutic interventions, Ovid Therapeutics, Inc. has embarked on a groundbreaking journey with their patented methods and compositions for the treatment of epileptic disorders. The patent, a testament to their innovative strides, delves into the intricate landscape of managing epilepsy, a condition affecting millions worldwide.
Epileptic disorders are known for their complexity, often requiring a multifaceted approach to treatment. Ovid believes their approach – OV329 – is significantly more potent than prior GABA-AT inhibitors which may confer seizure reduction efficacy, enhanced safety, and lower dosing.
Ovid’s approach uses a next-generation GABA-aminotransferase (GABA-AT) inhibitor to treat even the most rare and treatment-resistant forms of epilepsy and seizures. The mechanism of action targets GABA – the main inhibitory neurotransmitter in the brain. Low levels of GABA in the brain have been linked to neuronal hyperexcitability, which can lead to seizures. GABA is readily catabolized by the enzyme, GABA-AT. By targeting and inhibiting this enzyme, GABA catabolization can be limited and those who have low levels are protected from the levels dropping even lower. In this approach, those at risk of seizures as a result of low GABA levels are protected.
OV329 is currently in a Phase 1 study with healthy volunteers to evaluate the safety, pharmacokinetic profile and target engagement associated with single and repeated oral doses of OV329. The Phase 1 study will measure two potential biomarkers for target engagement via magnetic resonance spectroscopy (MRS) and transcranial magnetic stimulation (TMS). Ovid is also exploring acute treatment options with a potential IV formulation of OV329.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
